Your browser does not allow JavaScript!
JavaScript is necessary for the proper functioning of this website. Please enable JavaScript or use a modern browser.
Open Science Slovenia
Open Science
DiKUL
slv
|
eng
Search
Browse
New in RUL
About RUL
In numbers
Help
Sign in
2023 global inventory of commercial molecular tests for human papillomaviruses (HPV)
ID
Poljak, Mario
(
Author
),
ID
Oštrbenk Valenčak, Anja
(
Author
),
ID
Cuschieri, Kate S.
(
Author
),
ID
Bohinc, Klara
(
Author
),
ID
Arbyn, Marc
(
Author
)
PDF - Presentation file,
Download
(1,87 MB)
MD5: 621D4791137E0ED78D4C4D8D63D46F67
URL - Source URL, Visit
https://www.sciencedirect.com/science/article/pii/S1386653224000337
Image galllery
Abstract
To suit the needs of the human papillomaviruses (HPV) community comprehensively, a range of commercial HPV tests with different performance characteristics are required. Four periodic inventories of commercial HPV molecular tests present in the global market were published previously in 2010, 2012, 2015 and 2020. For the fifth inventory, data were retrieved from internal files and a detailed search using the main bibliographic databases as well as general internet search without period or language restrictions was performed in December 2023. At least 264 distinct HPV tests (and 511 test variants) were available globally in December 2023. A small 2020–2023 net increase in total numbers was observed, but with a strong introduction/withdrawal dynamic: 86 new distinct HPV tests (and 141 variants) were introduced and 76 tests (and 55 variants) were withdrawn from the market in the last four years. Although quality improvement of some tests was recorded, half of all HPV tests are still without a single peer-reviewed publication, and 79 % of tests are without published evidence that demonstrate performance characteristics are in line with requirements agreed in the HPV community. Only a relatively small pool of tests fulfill the operational/performance characteristics required to meet the global cervical cancer screening challenge. Although clinical and analytical performance characteristics of many commercial HPV tests are largely unknown, such tests are used worldwide in daily clinical practice and research, with potentially deleterious consequences. Due to this long-lasting unfavorable situation, significant scope for improvement persists for both manufacturers of HPV tests and the HPV community.
Language:
English
Keywords:
cervical cancer
,
HPV
,
human papillomaviruses
,
screening
,
test
Work type:
Article
Typology:
1.02 - Review Article
Organization:
MF - Faculty of Medicine
Publication status:
Published
Publication version:
Version of Record
Year:
2024
Number of pages:
8 str.
Numbering:
Vol. 172, art. 105671
PID:
20.500.12556/RUL-156261
UDC:
618.1
ISSN on article:
1873-5967
DOI:
10.1016/j.jcv.2024.105671
COBISS.SI-ID:
195047171
Publication date in RUL:
16.05.2024
Views:
375
Downloads:
458
Metadata:
Cite this work
Plain text
BibTeX
EndNote XML
EndNote/Refer
RIS
ABNT
ACM Ref
AMA
APA
Chicago 17th Author-Date
Harvard
IEEE
ISO 690
MLA
Vancouver
:
Copy citation
Share:
Record is a part of a journal
Title:
Journal of clinical virology
Publisher:
Elsevier
ISSN:
1873-5967
COBISS.SI-ID:
23214341
Licences
License:
CC BY-NC 4.0, Creative Commons Attribution-NonCommercial 4.0 International
Link:
http://creativecommons.org/licenses/by-nc/4.0/
Description:
A creative commons license that bans commercial use, but the users don’t have to license their derivative works on the same terms.
Secondary language
Language:
Slovenian
Keywords:
rak materničnega vratu
,
HPV
,
humani papiloma virusi
,
presejanje
,
test
Projects
Funder:
EC - European Commission
Funding programme:
H2020
Project number:
847845
Name:
Risk-based screening for cervical cancer
Acronym:
RISCC
Funder:
ARIS - Slovenian Research and Innovation Agency
Project number:
P3-0083
Name:
Odnosi parazitskega obstajanja
Similar documents
Similar works from RUL:
Similar works from other Slovenian collections:
Back